Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The overall results demonstrated that SRD5A2 rs9282858 polymorphism was remarkably associated with increased susceptibility of PCa (TT vs. AA: OR = 4.08, 95% CI = 1.94-8.58; TT + AT vs. AA: OR = 1.28, 95% CI = 1.11-1.47; TT vs. AA + AT: OR = 4.44, 95% CI = 2.12-9.27; allele T vs. allele A: OR = 1.34, 95% CI = 1.17-1.54).
|
28489754 |
2017 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although there was no overall association between V89L and prostate cancer risk, A49T might play a role in the etiology of prostate cancer among Caucasians.
|
23277398 |
2013 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The authors found that prostate cancer was not associated with V89L (L allele vs. V allele: odds ratio = 0.99, 95% confidence interval: 0.94, 1.05) and was probably not associated with A49T (T allele vs. A allele: odds ratio = 1.10, 95% confidence interval: 0.86, 1.40).
|
19914946 |
2010 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study tested the interactions of VDR (CDX2, FokI) and SRD5A2 (V89L, A49T) polymorphisms, and their associations with prostate cancer.
|
18483391 |
2008 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
After evaluating more than 6000 cases and 6000 controls, there is little evidence of a role for the SRD5A2 A49T variant in prostate cancer</span> risk.
|
18469342 |
2008 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Carriers of the rarer A49T A allele were at a 60% higher risk of prostate cancer (OR = 1.60; 95% CI 1.09-2.36; p = 0.02) and 50% lower risk of vertex and frontal balding (p = 0.03) compared with men homozygous for the more common G allele.
|
17136762 |
2007 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prostate cancer and BPH were not associated with the alanine-49 to threonine single nucleotide polymorphism and the (TA)n repeat.
|
16018939 |
2005 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results do not support the hypothesis that the V89L and A49T polymorphisms in the SRD5A2 gene are related to the risk of prostate cancer, but are compatible with the suggestion from earlier studies that men who are homozygous for the TA(9) or (18) alleles and men who have the TA(9)/TA(18) genotype are at a modestly reduced risk.
|
12712437 |
2003 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The A49T and TA repeat polymorphisms may have a modest effect on prostate cancer susceptibility, but bias and chance findings cannot be excluded; any genuine genetic effects would account only for a small proportion of prostate cancer in the population.
|
12869400 |
2003 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk.
|
12042668 |
2002 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To provide etiological clues, we evaluated the relationships of four polymorphic markers in the SRD5A2 gene, specifically, A49T (a substitution of threonine for alanine at codon 49), V89L (a substitution of leucine for valine at codon 89), R227Q (a substitution of glutamine for arginine at codon 227), and a (TA)n dinucleotide repeat, with prostate cancer risk in a population-based case-control study in China, a population with the lowest reported prostate cancer incidence rate in the world.
|
11588134 |
2001 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results argue against a prominent role of the A49T variant as a genetic risk factor for prostate cancer development and progression in the Finnish population.
|
11355945 |
2001 |
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The A49T variant of the SRD5A2 gene may be a significant contributor to the incidence of prostate cancer in African-American and Hispanic men in Los Angeles.
|
10501358 |
1999 |